Imatinib treatment of metastatic GIST: don't stop (believing).
Heinrich
Michael C
MC
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D006801:Humans; D000068877:Imatinib Mesylate; D015337:Multicenter Studies as Topic; D018365:Neoplasm, Residual; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate